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Common variable immunodeficiency (CVID) refers 
to a heterogeneous immunodeficiency syndrome 
characterized by hypogammaglobulinemia, 
recurrent bacterial infections and a variety of 
immunological abnormalities. Affected persons are 
prone to recurrent bacterial infections, especially 
involving the upper and lower respiratory tracts. In 
addition, patients exhibit increased susceptibility to 
a protean array of autoimmune, gastrointestinal, 
neoplastic, and inflammatory disorders1, 2. 
 
Epidemiology 
Although CVID is a rare condition, it is probably 
the most common symptomatic primary 
immunodeficiency syndrome encountered by the 
allergy/immunology and pulmonary specialist 1. Its 
prevalence ranges from 1:25.000 among Caucasians 
to 1:100.000 in the Japanese population, and affects 
men and women equally3.  
The majority of patients exhibit symptoms either in 
childhood or late-adolescence and present mainly 
with sinopulmonary infections4. However, in some 
patients, the disease does not become clinically 
apparent until the second or third decade of life, 
frequently with some delay between initial onset of 




In some cases, family members of CVID patients 
may have selective IgA deficiency (sIgAD), and 
cases of sIgDA may gradually progress to CVID, 
leading to the hypothesis that these humoral 
immunodeficiencies may be genetically related6. 
First-degree relatives of CVID patients are at risk to 
develop CVID/sIgAD. Most of the CVID families 
show an autosomal dominant trait, while only about 
20% of these familial cases are autosomal 
recessive7, 8. Various groups have made association 
between sIgAD & CVID and major 
histocompatibility complex (MHC) Class II/III. The 
+448 polymorphism of the TNF-α gene has been 
associated with granulomatous form of CVID9. A 
large microsatellite linkage study of 101 multiple 
case families with sIgAD and CVID demonstrated a 
strong susceptibility locus (IGAD1) lying in the 
telomeric part of the Class II region or the 
centromeric part of the MHC Class II region of 
chromosome 610, 11.  
Recent evidence suggests a role for the inducible 
co-stimulatory molecule (ICOS), a member of the 
CD28/CTLA4 family. ICOS is expressed on 
activated T cells, its ligand (B7H) is expressed on B 
cells and non-immune cells following inflammatory 
stimuli. ICOS has a role in T-cell activation and 
proliferation as well as humoral immunity; it is 
critical for CD40-mediated antibody class 
switching12-14. Grimbacher and associates15 
demonstrated ICOS deficiency on activated T cells, 
as a mongenic cause for CVID, in two families with 
autosomal recessive trait. In addition, mutations in a 
gene called TACI (transmembrane activator and 
calcium-modulator and cyclophilin ligand 
interactor) were found in 5-10% of CVID cases. 
TACI is a TNF-like receptor that is selectively 
expressed on B cells and induces T cell-
independent immunoglobulin class switch 
recombination when it interacts with other ligands 
on B cells like APRIL (a proliferative-inducing 
ligand)16. The discovery of ICOS and TACI 
mutations in a subset of patients with CVID points 
to problems in co-stimulation in CVID. 
  
Immunological features 
B- cell abnormalities 
The hallmark of CVID is hypogammaglobulinemia 
and impaired specific antibody production17. In 
patients with CVID, IgG levels are reduced to 
greater than 2 SDs below the mean. Most patients 
have low levels of IgA, and many have reduced 
IgM levels. Some authorities recommend that low 
serum IgA must be included in the diagnostic 
criteria for CVID4,18-20. Documenting impaired 
production of specific antibodies (isohem-
agglutinins and /or poor response to one or more 
vaccines) is essential for diagnosis. Numbers of B 
cells in the peripheral blood may be normal or 
reduced; approximately 13% of patients will have a 
B-cell count of less than 3% among peripheral 
blood lymphocytes4, 21.   
 
T-cell abnormalities 
Although CVID is classified as a form of 
predominantly humoral immunodeficiency, T-cell 




reduction in peripheral T-cell populations, as well 
as functional defects such as reduced in vitro 
proliferative responses, defects in cytokine 
production (reduced IL-2,4 and 9 ; increased IL-12, 
TNF-α and IFN-γ), decreased T-helper cell (CD4) 
count and in particular CD45-RA number as well as 
defects in T-cell function, abnormalities in T-cell 
signaling, diminished expression of the co-
stimulatory molecule CD40L, and increased 
suppressor T-cell number24.  
Some CVID patients exhibit an abnormally low 
CD4/CD8 ratio that, in most cases, is caused by 
both an increase in the absolute number of CD8+ T 
cells that co-express CD57 and a decrease in the 
absolute number of CD4+ T cells. The expanded 
population of CD8+ CD57+ T cells in these patients 
has functional properties that are characteristic of 
activated cytotoxic T lymphocytes24. Expansion of 
CD8+CD57+ T cells has also been observed in a 
number of other clinical conditions including 
cytomegalovirus infection, acute Epstein-Barr virus 
infection and HIV infection. The origin and 
functional significance of the expanded population 
of CD8 T cells in this subgroup of CVID patients is 
unclear. These CD8+ cells are capable of 
suppressing B cell immunoglobulin secretion in 
vitro1. However, most patients with this phenotype 
also exhibit in vitro B cell abnormalities suggesting 
that T cell suppression is not the primary cause of 
hypogammablobulinemia. Clinically, this subgroup 
of patients may exhibit a higher frequency of 
splenomegaly and granulomatous inflammation26. 
Whether not any of the above T cell abnormalities 
are responsible for abnormal in vivo antibody 
secretion in CVID, they emphasize that CVID is not 
merely a syndrome of defective immunoglobulin 
secretion; rather, it represents a generalized state of 
immune dysregulation characterized by functional 
abnormalities of both T and B cells. Clinically, this 
is reflected in the susceptibility of these patients to 
a variety of conditions not easily explained on the 
basis of isolated humoral immune defect1.  
Moreover, the recovery of Ig production (mostly 
IgG and IgM) transiently or permanently following 
human immunodeficiency virus (HIV) infection27 
and hepatitis C virus (HCV) infection28 has been 
reported in patients with CVID. These cases 
indicate that CVID is associated with potentially 
reversible defects in immunoregulatory factors and 
intact B-cell systems.  
 
Diagnosis  
CVID is a diagnosis of exclusion. Therefore, any 
other cause of hypogammaglobulinemia needs to be 
ruled out. Among those, the most important 
conditions are listed in table 1. 
Clinical manifestations of CVID include recurrent 
infections, autoimmune disease, lymphoid 
hyperplasia, granulomatous diseases, and 
malignancy.  
 
Recurrent infections  
Recurrent pyogenic infections of upper and lower 
respiratory tract are the main clinical manifestations 
of CVID3,29-31. Symptoms may appear during 
childhood or, more often, after puberty21. 
Bronchiectasis may develop if optimal therapy is 
delayed32-34. Haemophilus influenzae, Moraxella 
catarrhalis, Streptococcus pneumoniae, and 
Staphylococcus aureus are the organisms most 
commonly involved. A few patients with CVID 
present with unusual organisms, such as 
Pneumocystis carinii, mycobacteria, or various 
fungi. Mycoplasma pneumoniae infections in the 
urinary tract, joints, and deep abscesses have been 
reported4. Persistent diarrhea and malabsorption 
caused by Giardia lamblia also have been reported 
in patients with CVID30.  
Meanwhile, patients with CVID tolerate viral 
infections normally, but some exceptions exist. 
Severe and recurrent infections with herpes simplex 
are common, and herpes zoster eventually 
developed in as many as 20% of patients with 
CVID32. In addition, several cases of severe 
infections caused by cytomegalovirus have been 
reported in CVID patients35. Some patients may 
develop unusual enteroviral infections with a 
chronic meningoencephalitis and a dermato-
myositis-like illness. Presenting symptoms are 
either acute or insidious, with signs of encephalitis, 
seizures, headache, sensory motor disturbances, and 
personality changes29. The most common 
enteroviral pathogens are echoviruses, especially 
echovirus-11. The diagnosis can be made by culture 
or polymerase chain reaction amplification (PCR) 
of cerebrospinal fluid. High-dose IVIG or 
intrathecal immunoglobulin has been reported to be 
of benefit to some patients; however, this syndrome 
is progressive and fatal36.  
 
Autoimmune diseases and CVID  
Approximately 20% of CVID patients will develop 
one or more autoimmune disease20 indicating that 
CVID is a disease of abnormal immune regulation 
as well as immunodeficiency. The most common 
autoimmune diseases are autoimmune (Coombs 
positive) hemolytic anemia and immune 
thrombocytopenia. Neutopenia is also seen in a 
significant number of patients with CVID and in 
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some cases antigranulocyte antibodies have been 
demonstrated. Paradoxically, these patients are 
unable to mount an antibody response to infecting 
microorganisms but retain the ability to produce 
autoantibodies against red blood cells, platelets and 
granulocytes1. A variety of other autoimmune 
conditions have been associated with CVID. These 
include rheumatoid arthritis, systemic lupus 
erythematosus, polymyositis, vasculitis, 
autoimmune thyroid disease, Adddison disease, 
diabetes mellitus, biliary cirrhosis, Gillian-Barre 
syndrome, alopacia totalis and sicca syndrome. 
Females with CVID are more prone to develop 
these conditions4.  
 
Gastrointestinal disease 
Patients with CVID suffer from a variety of 
infectious and non-infectious gastrointestinal 
diseases. As many as 60% of untreated CVID 
patients will develop diarrhea. Giardia lamblia is 
the most common infectious cause. The diarrhea 
may be quite severe or prolonged, but usually 
respond to therapy with metronidazole. Other 
infectious causes of diarrhea include bacterial 
pathogens commonly associated with diarrhea such 
as Salmonella, Shigella, Yersinia and 
Campylobacter species30,37. Approximately 20% of 
these patients have a severe gastroenteropathy with 
severe malabsorption resembling celiac sprue, 
nodular lymphoid hyperplasia, and chronic 
inflammatory bowel disease such as ulcerative 
colitis and Crohn's disease1. Although regular Ig 
therapy reduces susceptibility to Giardia and 
Campylobacter enteritis, it does not prevent 
autoimmune mucosal inflammation since Ig 
replacement therapy does not affect the clinical 
course of inflammatory bowel disease38. 
Meanwhile, a small number of patients develop 
achlorhydria and pernicious anemia, autoimmune 
hepatitis and primary biliary cirrhosis1.  
 
Lymphoid hyperplasia and granulomatous diseases  
Approximately 30% of patients with CVID will 
have splenomegaly, diffuse lymphadenopathy, or 
both1,3. Other sites, such as the lungs (lymphoid 
interstitial pneumonitis), GI tract, skin, spleen, 
liver, and parotid gland, may be involved by these 
lymphoproliferative processes34,39. Lymph nodes 
show reactive follicular hyperplasia, atypical 
hyperplasia, or non- casiating granulomatous 
inflammation resembling sarcoidosis40. Nodular 
lymphoid hyperplasia in the GI tract has also been 
described in patients with CVID1. Granulomas have 
been reported in approximately 5-10% of patients 
with CVID41. In the lungs, these granulomas are 
indistinguishable from those of classic 
sarcoidosis40.  
 
Increased risk of malignant neoplasms  
Patients with CVID have a high risk of developing 
malignant neoplasms, such as non-Hodgkin 
lymphoma, GI carcinoma, or malignant lymphoma. 
Most of these are of the B-cell immunophenotype 
and frequently are associated with EBV40.  
Lymphoma occurs 300 times more frequently in 
women with CVID than in affected men. Malignant 
lymphomas in patients with CVID occur most 
frequently in the fifth to seventh decade and not in 
childhood. These malignant lymphomas usually are 
extranodal and histologically are intermediate- to 
high-grade non-Hodgkin lymphomas. Most of these 
lymphomas are of the B-cell immunophenotype and 
may be associated with EBV42. Patients with CVID 
also are at risk for gastric carcinoma 47 times 
higher than normal. Other malignancies include 
colon cancer, breast cancer, gastric cancer, prostate 
cancer, ovarian cancer, oral cancer, and melanoma1. 
 
Diagnostic considerations 
The diagnosis of CVID should be suspected in any 
patient with recurrent bacterial infections of the 
upper and lower respiratory tract40. In contrast to 
primary combined immunodeficiency disorders and 
HIV disease, children with CVID may not present 
with failure to thrive42. Before commencing 
laboratory studies to evaluate for possible humoral 
immunodeficiency, a careful medical history should 
be obtained, with attention to the basis on which 
prior infections were diagnosed. In addition, family 
history should be obtained and a careful physical 
examination performed. Other conditions, such as 
allergies, anatomic abnormalities of the respiratory 
tract, ciliarry dysmotility syndrome, cyctic fibrosis, 
and complement deficiency should be considered in 
the differential diagnosis1. 
Laboratory evaluation of the humoral immune 
system includes measuring of serum IgM, IgG, IgA 
and IgG subclasses, and comparing the values 
obtained with age-standardized reference ranges 6. 
It is also important to determine the ability to mount 
an antibody response to specific antigen, by 
measuring titers against microorganisms to which 
natural or vaccine exposure is common, such as 
tetanus, diphtheria, and rubella. Isohemagglutinin 
can provide a measure of the capacity to mount a 
specific IgM response in patients older than 1 year 
with appropriate ABO blood types. Immunization 
with tetanus toxoid and polyvalent pneumococcal 
vaccine may be used to evaluate functional 
antibody responses to protein and polysaccharide 
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antigens respectively. A 4-fold rise in anti-tetanus 
titers 3 to 4 weeks after immunization is considered 
normal, and at least a 2-fold rise in titers against 
most pneumococcal serotypes examined is 
considered a normal response in children older than 
2 years1,23. 
Various attempts have been made to subclassify 
CVID based on antibody production in culture 
systems44 or clinical and laboratory features45, but 
these are not in routine clinical use. A more recent 
method, currently in development for subdividing 
CVID, which correlates well with the groups of 
Bryant et al44 and clinical categories, is the Freiburg 
classification46. This uses flow cytometric analysis 
of CD19 gated B cells (excluding those CVID 
patients with low B cell numbers or granulomatous 
complications) to define CVID Group I with a 
severe deficiency of switched memory B cells. 
Group I is further subdivided into Ia with elevated 
immature B cells, which is associated with 
splenomegaly and autoimmune cytopenias, and Ib 
with normal numbers of immature B cells (figure 
1). This system is likely to be applied more widely 
as it is much simpler to perform than previous 
systems but needs validation across other patients’ 
cohorts. 
 
Differential diagnosis  
The differential diagnosis of CVID includes other 
causes of hypogammaglobulineia listed in table 1. 
The family history and the age of onset of 
symptoms are important, because patients 
presenting after 15 years are unlikely to have one of 
the known single gene primary 
immunodeficiencies. Various single gene disorders 
causing hypo-immunoglobulinemia should be 
excluded, including ‘leaky’ severe combined 
immunodeficiency (SCID), which can rarely 
present after childhood47. Male patients with low 
numbers of circulating B cells should be screened 
for X- linked agammaglobulinemia (XLA), and 
other autosomal recessive causes of 
agammaglobulinemia considered in females43. Also, 
males with X-linked hyper IgM or X-linked 
lymphoproliferative syndrome may be confused 
with CVID, since the former may have normal 
serum IgM levels48. 
There is no confusion with secondary 
hypogammaglobulinemia, in which IgA levels are 
usually moderately low. Nevertheless, routine 
screening for nephrotic syndrome, chronic 
lymphocytic leukemia (CLL) and myeloma should 
not be forgotten. Protein loosing enteropathy with 
low immunoglobulins can be confusing, but is 
usually obvious when serum IgG fails to rise on 
immunoglobulin therapy8. 
Hypogammaglobulinemia can also be induced by a 
variety of drugs listed in table 1. However, the 
deficiency is apparently reversible after cessation of 




Immunoglobulin replacement therapy 
The mainstay of therapy in CVID remains 
replacement IVIG therapy, which has replaced 
intramuscular immunoglobulin as there are fewer 
side effects and a greater amount can be     
infused49-51. Patients with CVID showed a reduction 
in the infection rate after the administration of 
regular IVIG50. The optimal trough level required to 
prevent infection in CVID has not been established, 
however, a dose of 200-400 mg/kg of IVIG given 
every 2-4 weeks would be sufficient. Early 
diagnosis is important so that IVIG replacement 
therapy can be commenced before the onset of 
irreversible organ damage51. 
Subcutaneous immunoglobulin (SCIG) therapy has 
become increasingly popular particularly in 
children and patients with poor venous access. 
SCIG is given more frequently (2 to 3 times a 
week), however, in terms of efficacy both SCIG 
and IVIG were found to be equally effective52,53. 
In order to improve and standardize the care and 
monitoring of patients with CVID receiving IVIG, 
Sewell and associates38 proposed a useful form of 
guidelines listed in table 2. 
 
Antibacterials   
The other mainstay of therapy in CVID is 
antibacterials, which are used as treatment for 
breakthrough infections, as prophylaxis in patients 
with recurrent infections despite adequate doses of 
IVIG therapy and in suppurative lung disease54,55. 
Optimum prophylactic antibacterial therapy in 
patients with CVID remains to be determined; 
although numerous regimens are used clinically on 
a purely empirical basis38. 
 
Corticosteroids 
Despite CVID is an immunodeficiency, there are 
some occasions when immunosuppression with 
corticosteroids is required, for example to control 
CVID associated granulomatous conditions and 
inflammatory bowel disease. This therapy carries 
the potential risk of precipitating overwhelming 
infection38. 
Corticosteroids may also be used in the treatment of 
CVID associated immune thrombocytopenia (ITP); 
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however, other modalities of therapy such as high 
dose IVIG, anti-Rhesus D antibodies or anti-B-cell 
therapy with rituximab may be considered.  
Rituximab, an anti-CD20 monoclonal antibody, is 
an attractive therapy since any subsequent lowering 
of Ig production is unlikely to be of concern in view 
of ongoing IVIG replacement; however, it has not 




In special conditions such as bronchiectasis, surgery 
may be indicated to remove localized area of 
diseased lungs. Also, splenectomy may be indicated 
to treat thrombocytopenia or granulomatous 
disease38. 
 
Immunomodulatory  agents 
I. Cytokines 
T cells from patients with CVID have numerous 
functional defects including low production of IL-2. 
Patients with CVID when treated with weekly 
subcutaneous human recombinant IL-2 conjugated 
to polyethylene glycol (PEG-IL-2), showed 
enhanced T cell proliferation, boosted B cell 
differentiation factor (BCDF) secretion and B cells 
responsive to signals after 12 weeks of therapy59. 
These data suggest some potential benefit from this 
form of therapy, but further work on longer and 
larger studies are required for validation of such 
therapy. 
IL-10 plus anti-CD40 in vitro can enhance IgG and 
IgA production by B cells from patients with 
CVID60. This effect has not been established in vivo 
in CVID patients. However, therapy with IL-10 is 
an area of active research in Crohn’s disease61 that 
may also have important implications for treatment 
of patients with CVID38. 
 
II. Vitamin A and analogues 
In addition to its antioxidant effect, vitamin A has 
an immunoregulatory effect in patients with 
immunodeficiency including an influence on 
cytokine production (TNF-α, IL-2 and IL-4) and 
lymphocyte growth and function62. Decreased 
serum vitamin A levels in CVID patients has been 
reported62. Reichenbach and associates63 reported a 
significant increase in serum IgA and IL-10 
together with a remarkable decrease in serum TNF-
α and neoptrin levels after the administration of 





III. Cimetidine and ketoprofen 
Both cimetidine (histamine receptor type-2 [H2] 
antagonist) and ketoprofin (cyclooxygenase 
inhibitor) have mild immunoregulatory properties, 
mainly enhancing cell mediated immunity by 
increasing proliferative responses to mitogens and 
antigens and inhibiting T cell suppression. 
However, studies concerning their efficacy as 
immunomodulators in vivo remain to be proven38.     
 
Vaccination in CVID 
The use of live vaccines in CVID is contraindicated 
in view of the possibility of prolonged excretion of 
a virus such as polio, which may then have the 
opportunity to revert back to virulence1. CVID 
patients may fail to eliminate attenuated live 
poliovirus, and should be immunized with killed 
rather than live polio vaccine64. Vaccine-associated 
paralytic poliomyelitis (VAPP) in a patient with 
CVID has been reported; this patient developed 
paralytic poliomyelitis 7 years after the last 
administration of trivalent oral poliovirus vaccine64. 
Even the use of killed vaccines is probably 
ineffective in view of reduction in antibody, 
memory B cells and T cell responses. However, it 
has been argued that despite a poor antibody 
response, T cell responses may be partially intact 
and, therefore, there may be merit in vaccinating to 






































Figure 1. Freiburg classification of common variable immunodeficiency (CVID)46.  
This shows the flow cytometric classification of CVID patients with normal B cell numbers. Patients with 
granulomatous complications have been excluded. The classification correlates well with the previous functional 
categories of Bryant et al 44. Group I includes previous categories A and B and Group II contains category C. Early 
evidence also suggests that Groups II and Ib may retain limited vaccination responses, while Group Ia is associated with 
splenomegaly and autoimmune cytopenias. It is not clear if the splenomegaly is granulomatous in nature. Quoted from 
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Fenclofenac3          1 may affect IgG &IgA 
                                           2 may affect IgG2&IgA 
                                            3 may affect IgA  
Primary immunodeficiency  with 
predominantly antibody deficiency 
X- linked agammaglobulinemia (XLA) 
Autosomal recessive agammaglobulinemia 
Common variable immunodeficiency (CVID) 
Ig heavy-chain gene deletions 
κ Chain deficiency 
IgG subclass deficiency 
severe combined immunodeficiency (SCID), leaky type 
X-linked lymphoproliferative syndrome 
X-linked hyper IgM syndrome 
Non X-linked hyper IgM syndrome 
Transient hypogammaglobulinemia of infancy 
Inducible co-stimulator (ICOS) deficiency 
Caspase 8 deficiency 
 





Infectious diseases Human immunodeficiency virus (HIV) (primary in children) 
Congenital infection with rubella 
Congenital infection with cytomegalovirus (CMV)  
Congenital infection with Toxoplasma gondii 
Epstein-Barr Virus (EBV) (± underlying genetic susceptibility) 
 
Hematologic malignancies Chronic lymphocytic leukemia (CLL) 
Immunodeficiency with thymoma (Good syndrome) 
Non Hodgkin's lymphoma (NHL). 































































Hypogammaglobulinemia with onset greater than 2 years of age in the absence of known 
diseases or drugs causing antibody deficiency. Absent isohaemagglutinins and /or poor 
response to vaccines (no live vaccines). 




Liver function tests (ALP, ALT, bilirubin plus HBsAg and HCV PCR if indicated) 
Renal function tests including urinalysis 
Lung function tests 
Chest radiograph 
Circulating lymphocyte subsets (T, B, NK numbers) 
Circulating immunoglobulins, serum and urine electrophoresis 
If IgG >3g/L perform IgG subclasses, tetanus, Hib and pneumococcal Ab titers and other 
vaccinations/infections as appropriate 
Anti-IgA antibodies (if IgA is low/absent) 
CT scan of lungs (if respiratory symptoms or signs are present) 
Sputum culture (if productive cough) 
Store serum sample at –70°C 
 
IVIG or SCIG to maintain trough level at 5-8 g/L 
Assessment for home therapy training program 
Prompt treatment of infections and management of septic complications 
 
Record pedigree 
Explain inheritance patterns of CVID and provide patient handout 
Identify any affected relatives and advise patient how to proceed 
Give patient details of the primary immunodeficiency association and primary antibody 
deficiency booklet 
 
Outpatient visit every 6-12 months (or depending on clinical situation) 
Monitor infection frequency, complications of treatment and disease and overall health 
Four monthly liver function tests and trough IgG levels and CRP  
FBC 6-12 monthly (haematinics iron, TIBC, ferritin, B12 and folate as required) 
Annual circulating lymphocyte phenotypes 
Lung function tests annually: spirometry & lung volumes (imaging if indicated) 
Sputum culture (if productive cough).    
Ab: antibody; AID: activation-induced cytidine deaminase; ALP: alkaline phosphatase; ALT: alanine amino-
transaminase; BLNK: B-cell linker; CRP: C-reactive protein; CT: computed tomography; FBC: full blood count; 
HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; Hib: Haemophilus influenzae type b; IVIG: intravenous 
immunoglobulin; NK: natural killer cells; PCR: polymerase chain reaction; SCID: severe combined immunodeficiency; 
SCIG: subcutaneous immunoglobulin; TIBC: total iron binding capacity; X-HIM: X-linked hyper IgM syndrome; XLA: 
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